A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00556322 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

424

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Alimta or Taxotere
DRUG: erlotinib [Tarceva]

Sponsor

Hoffmann-La Roche